Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2010-08-24Clinical Trial Update: A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
This completed prospective observational study evaluated quality of life and costs in real-world patients treated with 90Y-Zevalin (ibritumo…
-
CLINICAL_TRIALS trial_result · 2010-08-02Clinical Trial Update: Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma [Phase 3]
A Phase 3 trial comparing Rituximab to Tositumomab with I-131 Tositumomab in relapsed follicular lymphoma has completed and posted results i…
-
CLINICAL_TRIALS research · 2010-06-28Clinical Trial Update: Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy
A clinical trial update evaluating patient- and lesion-specific prognostic factors for standard radioimmunotherapy in follicular lymphoma; s…
-
CLINICAL_TRIALS trial_result · 2010-05-17Clinical Trial Update: Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma [Phase 4]
Phase 4 trial evaluating the efficacy duration and toxicity of Rituximab–Fludarabine–Cyclophosphamide as first-line therapy and Rituximab as…
-
FDA approval · 2010-02-26FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)
The FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) from Cephalon, LLC, enabling revisions to its labeling …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2010-01-29Clinical Trial Update: Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma [Phase 2]
Phase 2 trial update of Dynavax's CpG 1018 adjuvant (1018 ISS) used after Rituxan in patients with B-cell follicular lymphoma; the study sta…
-
CLINICAL_TRIALS trial_result · 2009-12-29Clinical Trial Update: Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma [Phase 1]
This document notes the completion of a Phase 1 trial evaluating cellular adoptive immunotherapy in patients with relapsed or refractory fol…
-
FDA approval · 2009-10-16FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan (rituximab) from Genentech.
-
FDA approval · 2009-09-03FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)
The FDA approved a supplemental application for ZEVALIN (ibritumomab tiuxetan) submitted by Acrotech Biopharma Inc. This action updates ZEVA…
-
CLINICAL_TRIALS trial_result · 2009-03-12Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy [Phase 2]
A Phase 2 trial assessing the efficacy and safety of Zevalin (ibritumomab tiuxetan) as a subsequent treatment in patients with follicular ly…
-
CLINICAL_TRIALS trial_result · 2008-12-01Clinical Trial Update: Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy [Phase 3]
Phase 3 trial comparing Zevalin (ibritumomab tiuxetan) versus no treatment as consolidation in follicular lymphoma patients who achieved par…
-
CLINICAL_TRIALS trial_result · 2008-10-24Clinical Trial Update: High-Dose Therapy Treatment in Patients With Follicular Lymphoma [Phase 3]
A Phase 3 trial evaluating high-dose therapy for follicular lymphoma has completed. The update does not include results.
-
CLINICAL_TRIALS research · 2008-07-28Clinical Trial Update: Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma [Phase 2]
A Phase 2 clinical trial examining consolidation with Y-90 ibritumomab tiuxetan after R-CHOP induction in patients with high-risk Follicular…
-
CLINICAL_TRIALS trial_result · 2008-05-29Clinical Trial Update: Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma [Phase 2]
A Phase II trial evaluating CHOP-R followed by Zevalin and Rituxan in follicular lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2008-05-21Clinical Trial Update: Dietary Intervention in Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating a dietary intervention for follicular lymphoma; current status is unknown.
-
FDA approval · 2008-03-25FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)
FDA has approved a supplemental application for Zevalin (ibritumomab tiuxetan) filed by Acrotech Biopharma Inc.
-
CLINICAL_TRIALS trial_result · 2008-02-11Clinical Trial Update: VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma [Phase 2]
Phase 2 study evaluating Velcade (bortezomib) in combination with rituximab for relapsed or refractory indolent B-cell lymphoma has complete…
-
CLINICAL_TRIALS trial_result · 2007-11-14Clinical Trial Update: R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas [Phase 2]
This is a completed Phase 2 clinical trial evaluating the R-MegaCHOP-ESHAP-BEAM regimen in high-risk aggressive B-cell lymphomas, including …
-
FDA label_change · 2007-11-02FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)
FDA granted approval of a supplemental application for Zevalin (ibrutinomab tiuxetan) submitted by Acrotech Biopharma, resulting in updated …
-
CLINICAL_TRIALS trial_result · 2007-09-17Clinical Trial Update: Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab [Phase 1, Phase 2]
This clinical trial update reports Phase 1/Phase 2 results for untreated or transformed follicular lymphoma treated with I-131 labeled tosit…
-
CLINICAL_TRIALS trial_result · 2007-07-03Clinical Trial Update: Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden [Phase 3]
A Phase 3 trial for newly diagnosed follicular lymphoma with a large tumor burden has completed.
-
CLINICAL_TRIALS other · 2007-02-16Clinical Trial Update: Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma [Phase 3]
Phase 3 clinical trial comparing high-dose chemotherapy plus Rituximab versus CHOP plus Rituximab in high-risk follicular lymphoma.
-
CLINICAL_TRIALS trial_result · 2006-10-26Clinical Trial Update: Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab [Phase 2]
A Phase 2 clinical trial evaluating the safety and efficacy of fludarabine with cyclophosphamide and rituximab in Follicular lymphoma has co…